Enthusiastic, dedicated, self-driving, strong problem solving and creative researcher with the ability to work independently and collaboration with others in multidisciplinary drug discovery project teams. Strong experienced in designing and implementing in vivo pharmacology studies such efficacy, tolerability, and pharmacodynamic (PD) studies from early stage research and target validation to late stage clinical candidates for drug discovery. Ability to think critically, independently to drive project forward and demonstrated troubleshooting and problem-solving skills More than 10 years’ experience in pharmaceutical and biotech industry in designing and performing in vivo PK/ADME, PD and toxicological studies for screening drug candidates (small and large molecules) in rats, guinae Pi g mice and other species. Extensive designing and hands-on (IP, IV, SC, and PO dosing, blood and tissue collection) and expertise of employing multiple in vivo models including like Xenograft, Allograft, Metastasis, Patient derived xenograft cancer models, as well as Type 2 diabetes, Stroke, colitis (DSS, CD45RBhi T cell transfer, IL-10 KO), Arthritis (CIA, CAIA) lupus(NZB/W, MRL-lpr, Imiquimod), Asthma (ova and HDM), wound healing and renal ischemic-reperfusion injury to evaluate drug mechanism and function of efficacy. Protein purification and characterization, (chromatography such as, affinity, ion-exchange, hydrophobic, and size exclusion), ELISAs, Cell-based assay development, primary cells and tissue culture techniques, FACS, receptor binding assays and/or cell-based HTS assays development, DNA/RNA isolation, immunohistochemistry and H&E staining, and drug formulation and quality control of drug substance for release and stability tests. Effective team players in cross-functional teams, interpret experiments results independently with research resulting in 72 publications including top-tier journals Nature and Cell.
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma